Try our beta test site
712 studies found for:    "Migraine Disorders"
Show Display Options
Rank Status Study
21 Completed
Has Results
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
Condition: Migraine Disorders
Interventions: Drug: Placebo;   Drug: Combination Product (sumatriptan succinate/naproxen sodium)
22 Completed
Has Results
A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
Condition: Migraine Disorders
Interventions: Drug: sumatriptan and naproxen sodium combination tablet;   Drug: sumatriptan tablet;   Drug: naproxen sodium tablet
23 Completed
Has Results
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
Condition: Migraine Disorders
Interventions: Drug: Combination Product (sumatriptan succinate / naproxen sodium);   Drug: Placebo
24 Completed Biomarker Study in Participants With Migraine
Condition: Migraine Disorders
Intervention: Drug: Capsaicin
25 Active, not recruiting Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
Condition: Migraine Disorders
Intervention: Device: Occipital nerve stimulator
26 Active, not recruiting An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
Condition: Migraine Disorder
Intervention: Biological: ALD403 (Eptinezumab)
27 Completed
Has Results
Caffeine/Propranolol Intervention for Acute Migraine
Condition: Migraine Disorders
Interventions: Drug: caffeine/propranolol combination tablet;   Drug: placebo
28 Recruiting Transcranial Direct Current Simulation in Chronic Migraine
Condition: Migraine Disorders
Intervention: Device: TDCS
29 Completed BI 44370 TA in Acute Migraine Attack
Condition: Migraine Disorders
Interventions: Drug: BI 44370 TA Low Dose;   Drug: Eletriptan;   Drug: Placebo;   Drug: BI 44370 TA Medium Dose
30 Completed
Has Results
Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)
Condition: Migraine Disorders
Interventions: Drug: rizatriptan benzoate (5 mg);   Drug: rizatriptan benzoate (10 mg);   Drug: Rizatriptan 5 mg Placebo;   Drug: Rizatriptan 10 mg Placebo
31 Active, not recruiting A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
Condition: Migraine Disorders
Interventions: Drug: ALD403;   Drug: Placebo
32 Completed TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
Condition: Migraine Disorders
Interventions: Drug: Combination Product (sumatriptan succinate / naproxen sodium);   Drug: RELPAX(eletriptan) 40mg Tablet
33 Completed A Study of Gastric Delay in Migraine Patients (3207-003)
Condition: Migraine Disorders
Interventions: Drug: MK3207;   Drug: Comparator: Placebo (unspecified)
34 Recruiting Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
Condition: Migraine Disorders
Interventions: Biological: ALD403 (Eptinezumab);   Biological: Placebo
35 Completed
Has Results
The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine
Condition: Migraine Disorders
Interventions: Drug: NP101 - Sumatriptan iontophoretic transdermal patch;   Drug: Placebo
36 Active, not recruiting Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®
Condition: Migraine Disorders
Intervention: Other: No Intervention
37 Completed
Has Results
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
Condition: Migraine Disorders
Intervention: Drug: NP101
38 Completed
Has Results
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
Condition: Migraine Disorders
Intervention: Drug: NP101
39 Not yet recruiting Greater Occipital Nerve (GON) Block Effectivity in the Treatment of Chronic Migraine: 6 Months Follow up
Condition: Migraine Disorders
Interventions: Drug: bupivacaine;   Drug: saline
40 Completed An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
Conditions: Migraine Disorders;   Migraine
Intervention: Drug: GW274150

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.